30-day average of 15 articles · scale −100 to +100
Across 15 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Elevance Health news is Bullish (+55)
on a scale from −100 to +100.
That is up 19 points from the previous 30 days (+36).
📈 ELV shares up 33.6% in 12 months despite earnings valuation questions.
⚠️ Elevated behavioral health utilization may limit scaling of cost savings.
Somewhat Bullish +45
Elevance Health (ELV) Stock Looks Reasonable After Raised Earnings Outlook
AI-generated analysis
Key insights
📈 Elevance Health shares have gained 33.6% over the past 12 months, raising questions about whether current earnings fully support the price advance.
📉 The company trades at a P/E ratio of approximately 18.1x, which is well below the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
💰 Management has lifted its longer-term earnings outlook and flagged potential improvements in Medicaid margins to support future profit growth.
🛡️ Carelon's complex behavioral care programs have shown around 10% cost savings and reduced inpatient admissions, supporting value-based relationships.
🏥 Expansion of home-based CareBridge services into new markets aims to deepen revenue from health services and support margin resilience.
⚠️ Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests cost savings may not scale fast enough across the wider book.
📊 Analyst consensus narratives on Simply Wall St currently split between a bullish view of 9% undervaluation and a bearish view of roughly fair value.
⚖️ Despite a recent lawsuit over alleged fraudulent billing, the market continues to price Elevance Health at a discount to sector norms.
📈 Bullish signals
💰Management has lifted its longer-term earnings outlook, signaling confidence in future profit growth and operational efficiency.
📉The stock trades at a P/E ratio of approximately 18.1x, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x, suggesting potential undervaluation.
🛡️Carelon's behavioral care programs have demonstrated around 10% cost savings and reduced inpatient admissions, indicating strong operational performance.
🏥Expansion of home-based CareBridge services into new markets is expected to deepen value-based relationships and support future margin resilience.
📉 Risk factors
⚠️Persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments suggests that projected medical cost savings may not scale fast enough across the wider book.
⚖️A recent lawsuit over alleged fraudulent billing has put a spotlight on the company's risk controls, though the market currently prices the shares at a discount to sector norms.
Article
Elevance Health (ELV) shares have appreciated 33.6% over the past year, prompting investors to assess whether current earnings power justifies the valuation. The company recently raised its longer-term earnings outlook and highlighted potential improvements in Medicaid margins, which could enhance the durability and predictability of future profit growth within an earnings-based valuation framework.
Analysts covering Elevance Health are currently divided on the stock's fair value. Simply Wall St analysis suggests a bullish case where the stock is 9% undervalued, driven by expansion in Carelon's behavioral care programs that have demonstrated approximately 10% cost savings and reduced inpatient admissions. These initiatives aim to deepen value-based relationships and support margin resilience.
Conversely, a bearish perspective views Elevance Health as roughly fairly valued, citing concerns that persistent elevated utilization in behavioral health, specialty pharmacy, and emergency departments may prevent the projected medical cost savings from scaling effectively across the wider book of business. Despite these mixed analyst views, the stock trades at approximately 18.1x earnings, which is significantly lower than the broader Healthcare sector average of 25.3x and peer group averages near 31.4x.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Elevance Health has launched a suite of new digital and personalized care initiatives designed to simplify member experiences and improve health outcomes. The company is leveraging data, digital tools, and proactive outreach to connect members with necessary support through its health plans and Carelon healthcare services business.
A key component is the Proactive Member Engagement (PME) program, an enterprise-wide initiative that integrates medical, pharmacy, behavioral, and social data to anticipate member needs. Operating at scale with over 12 million interactions, PME uses advanced analytics to deliver timely, personalized outreach via text, phone, and email, helping members navigate care without fragmentation.
The company also introduced Total Movement Care (TMC), a new musculoskeletal (MSK) care experience aimed at connecting members to appropriate care earlier in their journey. TMC provides access to MSK-trained clinicians, virtual-first physical therapy, and guided navigation to specialists, initially rolling out to a subset of members in fully insured plans before expanding.
These initiatives reflect Elevance Health's broader strategy to create a coordinated, seamless experience for individuals managing chronic conditions. By combining real-time insights with continuous support, including 24/7 nurse access and tailored care plans, the company aims to reduce avoidable hospitalizations and empower members to manage their health confidently.
📊 Elevance Health launches PME using over 12 million interactions for personalized outreach.
🏥 Total Movement Care offers MSK-trained clinicians and virtual-first physical therapy services.
💊 PME integrates medical, pharmacy, behavioral, and social data to anticipate care needs.
📈 Programs aim to improve adherence and reduce avoidable emergency room visits.
📊 Elevance Health launched Proactive Member Engagement (PME), an enterprise-wide program utilizing over 12 million interactions to deliver personalized outreach via text, phone, and email.
🏥 The new Total Movement Care (TMC) initiative offers MSK-trained clinicians, virtual-first physical therapy, and specialist navigation for musculoskeletal conditions.
💊 PME integrates medical, pharmacy, behavioral, and social data to anticipate needs and identify gaps in care across the enterprise.
📱 Sydney Health provides personalized, real-time guidance using member benefits and care history to surface tailored nudges for scheduling appointments and screenings.
👩⚕️ Concierge Care offers ongoing support with dedicated teams and 24/7 nurse access to help members manage side effects and adjust care plans.
📈 These programs aim to improve medication adherence, increase wellness visits, and reduce avoidable emergency room visits and hospitalizations.
Bullish Signals
Over 12 million interactions demonstrate significant operational reach.
Integrated data anticipates needs and identifies care gaps.
Virtual-first physical therapy offers accessible musculoskeletal care entry.
Real-time insights simplify appointment scheduling and screenings.
Proactive engagement reduces ER visits and hospitalizations.
Bullish Signals
Elevance Health is scaling its Proactive Member Engagement program with over 12 million interactions, demonstrating significant operational reach in personalized outreach.
The integration of medical, pharmacy, behavioral, and social data allows the company to anticipate member needs effectively and identify care gaps proactively.
Total Movement Care introduces virtual-first physical therapy and MSK-trained clinicians, offering a streamlined and accessible entry point for musculoskeletal care.
Sydney Health utilizes real-time insights to translate complex care plans into actionable steps, helping members schedule appointments and complete screenings more easily.
The combination of proactive engagement and continuous support aims to reduce avoidable emergency room visits and hospitalizations, directly impacting cost containment and member health.
Major health insurers such as UnitedHealth, Elevance, Cigna, and Humana reported solid first-quarter earnings that exceeded analyst expectations, driven by seasonal factors like a milder flu season and weather-related disruptions to medical spending. These results have improved investor sentiment, with several companies raising their outlooks for 2026, though analysts emphasize that the true test of underlying performance has not yet arrived due to significant lags in claims processing. Baird analyst Michael Ha noted that while first-quarter numbers appear strong due to conservative pricing and lower-than-expected medical loss ratios, actual hard data on claims typically lags by one to two months, meaning Q2 will serve as the critical proving ground for whether costs are truly under control or merely temporarily suppressed.
Barclays analyst Andrew Mok added that the first-quarter beats were supported by strength across all major segments, including commercial coverage and Medicaid, but warned that investors must wait for more complete claims data in the second quarter to accurately assess if pricing strategies remain appropriate. A specific concern for Humana involves its aggressive growth plans for Medicare Advantage membership in 2026; Ha cautioned that similar growth by CVS Health in Q2 2024 was followed by missing medical loss ratio targets as costs eventually crystallized, suggesting investors should watch for repeating patterns where initial optimism gives way to cost pressures later in the year.
The broader context includes strategic shifts within the industry where insurers have exited less profitable markets and adjusted benefits to align with rising expenses, such as UnitedHealth discontinuing Medicare Advantage plans in 109 counties effective 2026. While these actions have created a pricing cushion that helped Q1 results, the sector remains vulnerable to small shifts in enrollment or member health profiles under the Affordable Care Act marketplace, which could significantly impact earnings as June brings more clarity through data like the Wakely analysis. Ultimately, the second quarter will determine whether the 2026 growth targets are sustainable or if the industry faces a significant underwriting hurdle that could alter year-end earnings projections.
📈 Q1 earnings beat estimates with strong reserve building and seasonal cost reductions.
⚠️ Analysts caution delayed claims make full financial validation dependent on Q2 results.
🏥 Companies shrink membership, exit markets, and cut plans to manage rising expenses.
❄️ Success hinges on clearing the underwriting hurdle as delayed data crystallizes in Q2.
📈 Major health insurers including UnitedHealth, Elevance, Cigna, and Humana reported solid first-quarter earnings that beat analyst estimates.
💼 Investor sentiment improved following these positive reports, with some companies also raising their long-term 2026 outlooks.
⚠️ Analysts caution that Q1 results are preliminary because of significant time lags in processing medical claims for full cost data.
📉 Insurers strengthened medical reserves, creating a financial cushion that supports their current positive earnings outlooks.
❄️ Some of the strong Q1 performance is attributed to seasonal factors like a milder flu season and weather disruptions suppressing costs.
💰 Industry-wide cost controls have helped lower medical loss ratios, a key metric showing costs as a share of premiums.
🏥 Companies are actively exiting less profitable markets and shrinking membership to better align with rising medical expenses.
🚫 UnitedHealth announced it will stop offering Medicare Advantage plans in 109 U.S. counties starting in 2026.
⏳ The second quarter is viewed as the real proving ground when delayed claims from Q1 finally crystallize into full data.
🎯 Analysts warn that clearing the "underwriting hurdle" in Q2 is essential for validating pricing and predicting positive 2026 earnings.
🔮 Humana faces specific scrutiny after planning 25% Medicare Advantage membership growth for 2026 while keeping benefits stable.
😰 Investors are concerned about a potential repeat of CVS Health's Q2 2024 results, where costs missed targets despite membership growth.
🏛️ The Affordable Care Act marketplace remains a critical area to watch for insurers like Centene, Molina, and Elevance in Q2.
📋 The upcoming Wakely analysis in late June will be key for determining if revenue assumptions match actual member health risks.
📉 Even minor shifts in enrollment or member health profiles could lead to significant earnings gains or losses for these insurers.
Bullish Signals
Major insurers beat Q1 estimates.
Insurers strengthened medical reserves.
Medical loss ratios were lower.
UnitedHealth exits unprofitable markets in 2026.
Humana aims for 25% MA growth in 2026.
Risk Factors
Q1 earnings rely on incomplete data with 1-2 month claim lags.
Q2 will test if medical costs stay below conservative estimates.
Analysts warn Q1 results require a grain of salt due to lag.
Humana risks missing loss ratio targets like CVS Health did in 2024.
Recent cost improvements may fail once full Q2 claims data arrives.
Bullish Signals
Major health insurers including UnitedHealth, Elevance, Cigna, and Humana all beat first-quarter analyst estimates, boosting investor sentiment.
Insurers have strengthened their medical reserves, adding a financial cushion that could support their outlooks for the remainder of the year.
Medical loss ratios came in lower than expected for several companies, indicating improved cost controls and efficiency in segments like commercial coverage, Medicare, and Medicaid.
UnitedHealth plans to exit less profitable Medicare Advantage markets starting in 2026, a strategic move that helps align pricing with rising medical expenses.
Humana expects to grow its Medicare Advantage membership by 25% in 2026 while maintaining stable benefits, similar to the successful pattern seen at CVS Health in 2024.
Improvements in cost controls and stabilizing medical costs have contributed to surprisingly solid results in Medicaid, even as states tighten eligibility.
The sector is benefiting from a milder flu season and weather disruptions that temporarily suppressed medical costs, providing a positive start to the year.
Risk Factors
Insurers reported solid Q1 results based on estimates and incomplete claims data due to a lag in processing hospital stays and procedures that take one to two months to review.
Second quarter will serve as the real test where delayed claims crystallize, potentially revealing whether medical costs are tracking lower than expected.
Analysts warn investors to take first-quarter earnings 'with a grain of salt' because current performance relies on estimates rather than real hard claims data.
Humana faces specific concerns after CVS Health repeated a pattern in 2024 where it grew Medicare Advantage membership but later missed medical loss ratio targets significantly due to higher-than-expected costs.
The industry is vulnerable if recent improvements driven by conservative pricing and market exits do not hold up when complete second-quarter data becomes available.
Even small shifts in enrollment or member health profiles could lead to meaningful earnings losses as revealed in the Wakely analysis released in late June.
Investors will be forced to rely on estimates for first-quarter results while waiting for clearer read on underlying cost trends that only come with more claims data in Q2.
Centene Corporation reported its first-quarter earnings in late April, revealing a counterintuitive financial story where the health insurer shed approximately 2 million members of its Affordable Care Act marketplace—reducing enrollment from 5.6 million to 3.6 million over the last year—while simultaneously generating $1.5 billion in net earnings and raising full-year profit guidance. Despite the significant drop in membership, adjusted earnings per share jumped to $3.37, surpassing Wall Street expectations, as the company successfully navigated the expiration of enhanced ACA subsidies on January 1, which triggered a sharp industry-wide average premium increase of 20% to 26%.
The strategy employed by Centene, along with peers like UnitedHealth and Elevance Health, involved raising premiums faster than customers departed, resulting in year-over-year revenue growth from $46.6 billion to $49.9 billion even as the marketplace book shrank by more than a third. This "adverse selection" effect means the remaining customer pool consists primarily of older, sicker individuals with chronic conditions who are less likely to drop coverage despite higher costs; Centene's commercial Health Benefit Ratio was 75.3%, reflecting this higher acuity. By pricing in these higher utilization rates for its 2026 plans and leveraging ACA risk-adjustment mechanisms that transfer funds from healthier member pools to sicker ones, the company maintained profitability after a challenging 2025 characterized by high medical spending and unfavorable mix.
While Wall Street has largely applauded this margin expansion following a brutal 2025 for insurers, the trend highlights a difficult dynamic for consumers facing premium hikes and narrower benefits as the insurance market shifts away from subsidized populations. Experts note that approximately 14% of ACA enrollees missed January 2026 payments, potentially shrinking the marketplace by up to 26% by year-end, meaning the discipline in pricing and member retention that drove profits for Centene is effectively transferring costs to the remaining households still enrolled in marketplace plans.
📉 Centene lost 2M customers after subsidy expiry but still earned $1.5B.
💰 Revenue grew while medical claims rose due to sicker remaining members.
⚠️ Consumers face higher premiums and narrow benefits as profits shift to insurers.
🏥 Centene Corporation lost approximately 2 million Affordable Care Act (ACA) marketplace customers in one year, dropping membership from 5.6 million to 3.6 million since the enhanced subsidies expired.
💰 Despite the massive customer loss, Centene reported $1.5 billion in net earnings for Q1 and raised its full-year profit guidance significantly.
📈 Adjusted earnings per share jumped to $3.37, which was well above Wall Street expectations despite the shrinking membership base.
📉 The insurance industry saw a 20% to 26% increase in premiums across the board after January 1st when subsidies ended, causing young and healthy customers to drop coverage.
💸 Centene's revenue grew year-over-year from $46.6 billion to $49.9 billion even as its marketplace book of business shrank by more than one-third.
🩺 The remaining customer pool is characterized by "adverse selection," meaning the people who stayed are older, sicker, and manage chronic conditions that require higher medical costs.
📊 Centene's commercial Health Benefit Ratio reached 75.3%, indicating a high share of premiums was paid out in medical claims due to the higher acuity of remaining members.
⚖️ Major insurers like UnitedHealth and Elevance Health followed the same strategy of raising prices while accepting smaller, sicker member pools to generate profits.
🔄 Insurers are utilizing ACA risk-adjustment mechanisms to transfer funds from plans with healthier members to those with sicker ones, smoothing out financial volatility.
📉 Analysts predict that 14% of ACA enrollees missed their January 2026 premium payments and the marketplace could shrink by up to 26% by year-end.
👥 Investors welcomed the margin expansion following a brutal 2025 for insurers squeezed by high medical spending and an unfavorable member mix.
💡 Consumers face higher premiums and narrower benefits as a direct result of market conditions that allow insurers to generate record profits.
🛒 Financial experts advise shoppers to carefully review options during open enrollment rather than auto-renewing their marketplace plans.
💳 Using a Health Savings Account paired with Bronze plans is recommended for consumers trying to manage costs despite higher premiums.
⚠️ Household subsidies are sensitive to income changes, as exceeding the 400% federal poverty level threshold can result in losing all subsidy benefits instantly.
📉 The expiration of enhanced ACA subsidies has ultimately hurt consumers more than insurers, contrary to initial expectations that the policy would damage insurance companies.
Subsidies vanish with just $1 over 400% federal poverty level.
Insurers faced high claims and unfavorable member mix in 2025.
Bullish Signals
Centene Corporation posted $1.5 billion in net earnings in the first quarter, demonstrating strong financial resilience despite market headwinds.
The company raised its full-year profit guidance, signaling management confidence in sustained profitability ahead of expectations.
Adjusted earnings per share jumped to $3.37, significantly outperforming Wall Street estimates and highlighting operational efficiency.
Revenue grew year-over-year from $46.6 billion to $49.9 billion during the quarter, expanding the top line even as customer numbers declined.
Centene's commercial Health Benefit Ratio of 75.3 percent slightly beat expectations, indicating effective cost management within a higher acuity member pool.
Major peers UnitedHealth (UNH) and Elevance Health (ELV) executed similar successful strategies of raising prices and maintaining profitability.
Wall Street has largely cheered the discipline shown by insurers in improving margins after a challenging 2025 period.
Risk Factors
Centene Corporation hemorrhaged customers, seeing its Affordable Care Act marketplace membership collapse from 5.6 million to 3.6 million in just one year—a drop of roughly 2 million people.
After enhanced ACA subsidies expired on January 1, young and healthy customers dropped coverage while older, sicker members remained, creating adverse selection that forced insurers to price higher premiums into plans.
The marketplace could shrink by as much as 26 percent by year-end, according to analysts at the consultancy Wakely, signaling a continued contraction in customer base.
Consumers are facing squeezed wallets due to premium increases, narrower benefits, and sicker risk pools, while one extra dollar above the 400 percent federal poverty level threshold can wipe out subsidies entirely.
After a punishing 2025 in which insurers were squeezed by high medical spending and an unfavorable member mix, rate hikes flowed almost directly to the bottom line rather than offsetting rising claim costs.
Centene Corporation reported its first-quarter results in late April, revealing a paradoxical scenario where the insurer lost approximately 2 million customers yet generated $1.5 billion in net earnings. This outcome occurred despite a significant drop in Affordable Care Act marketplace membership from 5.6 million to 3.6 million in just one year and industry-wide premium increases ranging from 20% to 26%. The company raised its full-year profit guidance, with adjusted earnings per share jumping to $3.37, which surpassed Wall Street expectations.
The financial resilience was driven by a strategic shift where the insurer retained a smaller but sicker member pool following the expiration of enhanced ACA subsidies on January 1. Younger, healthier customers left the market, leading to adverse selection where remaining members are older and managing chronic conditions, increasing the Health Benefit Ratio to 75.3 percent while reflecting higher acuity. Despite paying out more in claims, Centene's revenue grew year-over-year from $46.6 billion to $49.9 billion because premium hikes were priced into 2026 plans, allowing margins to expand significantly after a difficult 2025 characterized by high medical spending and unfavorable member mixes.
This strategy is not unique to Centene, as major competitors like UnitedHealth and Elevance Health employed similar tactics of raising prices and accepting smaller membership bases while utilizing the ACA’s risk-adjustment mechanism to transfer funds from healthier pools to sicker ones. While Wall Street largely cheered the improved margins and investor discipline, consumers face the opposite reality as premium increases, narrowed benefits, and a sicker risk pool squeeze household budgets. Experts warn that the marketplace could shrink by up to 26 percent by year-end if a significant portion of enrollees continue to miss premium payments, with roughly 14 percent already falling behind on January 2026 payments.
📉 Centene lost 2 million members as subsidies expired and premiums rose sharply.
💰 Company profits hit $1.5 billion despite smaller, sicker customer bases.
⚠️ Industry strategy prioritizes higher margins over consumer affordability and coverage breadth.
📉 Centene Corporation lost approximately 2 million ACA marketplace members in one year, dropping from 5.6 million to 3.6 million in membership.
💰 Despite the massive loss of customers, the company posted $1.5 billion in net earnings and raised its full-year profit guidance.
📈 Adjusted earnings per share jumped to $3.37, significantly surpassing Wall Street's expectations for the quarter.
💸 Industry-wide premium hikes averaged 20% to 26% after enhanced ACA subsidies expired on January 1, contributing directly to higher profits.
🔄 The remaining customer base shifted toward older, sicker individuals with chronic conditions due to young and healthy customers dropping coverage.
⚖️ This shift in member composition is known as "adverse selection," which improved margins by reducing the share of revenue paid for claims relative to premiums collected.
💼 Centene's commercial Health Benefit Ratio was 75.3%, indicating higher medical costs per enrollee but priced into the company's 2026 plan assumptions.
📊 Other major insurers like UnitedHealth and Elevance Health (ELV) followed the same strategy of raising prices while accepting a smaller, sicker member pool.
🏥 Analysts estimate that 14% of ACA enrollees missed their January 2026 premium payments, potentially shrinking the marketplace by up to 26% by year-end.
📉 Revenue for Centene still grew year-over-year from $46.6 billion to $49.9 billion despite the reduction in the marketplace book size.
⚠️ The post-subsidy cliff is now primarily hurting consumers through premium increases, narrower benefits, and sicker risk pools.
💡 Financial experts advise consumers to shop carefully during open enrollment rather than auto-renewing existing marketplace plans.
📊 Consumers should run the numbers on Bronze plans paired with Health Savings Accounts to manage costs effectively.
🚫 One extra dollar above the 400% federal poverty level threshold can result in the complete loss of ACA subsidies for consumers.
🏦 After a financially punishing 2025, investors rewarded insurance companies for improving margins rather than maintaining previous growth models.
Bullish Signals
Centene earned $1.5B net earnings despite losing 2M members.
EPS jumped to $3.37, surpassing Wall Street expectations.
Revenue grew from $46.6B to $49.9B year-over-year.
Premiums rose faster than member loss due to subsidy expiration.
Commercial Health Benefit Ratio hit 75.3%, exceeding forecasts.
Strategy mirrors peers UnitedHealth and Elevance Health.
14% of enrollees missed 2026 premiums; collections remain strong.
Margin expansion after rate hikes priced into 2026 plans.
Risk Factors
Centene lost 2M members, dropping enrollment from 5.6M to 3.6M.
Insurers rely on price hikes for sicker, smaller member pools.
Premiums jumped 20-26% after ACA subsidies expired Jan 1.
High costs and unfavorable mixes threaten long-term sustainability.
Wakely estimates 14% missed Jan payments; market may shrink 26%.
Bullish Signals
Centene Corporation posted $1.5 billion in net earnings despite losing roughly 2 million ACA marketplace members, demonstrating a highly resilient business model.
The company raised its full-year profit guidance and saw adjusted earnings per share jump to $3.37, significantly exceeding Wall Street expectations.
Revenue grew year-over-year from $46.6 billion to $49.9 billion in the quarter, showing strong top-line growth even as the marketplace book shrank by more than a third.
Centene raised premiums faster than members left the pool; industry-wide premiums jumped 20-26% due to the expiration of enhanced ACA subsidies on January 1.
The company's commercial Health Benefit Ratio came in at 75.3 percent, slightly above expectations, reflecting accurate pricing for higher acuity among remaining members.
Centene executed the same successful strategy as major peers UnitedHealth and Elevance Health, raising prices while accepting a smaller but more predictable membership base.
Analysts at consultancy Wakely estimate that 14 percent of ACA enrollees missed their January 2026 premium payments, indicating strong collection rates despite market contraction.
After a punishing 2025, the rate hikes flowed almost directly to the bottom line as margins expanded and priced into 2026 plans.
Risk Factors
Centene Corporation lost approximately 2 million Affordable Care Act marketplace members, causing its marketplace membership to collapse from 5.6 million to 3.6 million in just one year.
The insurer is relying on a strategy of raising prices while accepting a smaller, sicker member pool, creating significant adverse selection where remaining customers are older and have chronic conditions.
Industry-wide premiums jumped 20-26% after enhanced ACA subsidies expired on January 1, forcing households to pay sharply higher rates for potentially reduced benefits.
A brutal 2025 environment saw insurers squeezed by high medical spending and an unfavorable member mix, raising concerns about long-term sustainability if these rate hikes prove insufficient.
Analysts at consultancy Wakely estimate that 14 percent of ACA enrollees missed their January 2026 premium payments, with the marketplace potentially shrinking by as much as 26 percent by year-end.
The health insurance market and household budgets are moving in opposite directions, meaning consumers face squeezed wallets while insurers post record profits.
Insurers are transferring funds from insurers with healthier members to those with sicker ones via risk-adjustment mechanisms, masking the underlying decline in the overall membership base.
Cardinal Health (NYSE: CAH) is preparing to report its first-quarter earnings on Thursday before market hours, with the company having already surpassed analysts' revenue expectations in the previous quarter. Last quarter, Cardinal Health reported revenues of $65.63 billion, representing an 18.8% year-over-year increase. The company also beat analysts' full-year EPS guidance and current EPS estimates during that prior period. For the current quarter ahead of earnings, market expectations are for revenue growth of 13.5% year over year, which would mark an improvement from the flat revenue reported in the same quarter last year.
Analysts covering Cardinal Health have recently become more bullish, with a majority of revenue estimates seeing upward revisions over the last 30 days. Despite this recent positive sentiment and multiple beats against analyst estimates over the past two years, the company has missed Wall Street's revenue estimates multiple times in that same timeframe. This stands in contrast to some of its peers in the healthcare providers & services segment that have already reported their Q1 results; Elevance Health delivered 1.5% year-over-year revenue growth while beating expectations by 2.4%, and UnitedHealth reported revenues up 2%, topping estimates by 1.7%. Both Elevance Health and UnitedHealth saw their share prices increase following their respective reports, with the broader healthcare providers & services segment showing an average share price gain of 10.8% over the last month.
Current investor sentiment is reflected in Cardinal Health's stock price, which remains unchanged compared to a recent period, though it trades below its average analyst price target. The average analyst price target for Cardinal Health is set at $248.27, compared to the current share price of $206.15. These figures are based on data reported in an article dated Wednesday, April 29, 2026.
📅 CAH reports Q1 earnings Thursday before market open.
💰 Last quarter revenue hit $65.63B with 18.8% growth.
⬆️ Upward revisions and bullish sentiment raise estimates by 13.5%.
🏁 Analyst price target sits at $248.27 versus $206.15 current.
📅 Cardinal Health (CAH) is scheduled to report its Q1 earnings results this Thursday before market hours.
💰 Last quarter, Cardinal Health beat analysts' revenue expectations with total revenues of $65.63 billion.
📈 Year-over-year revenue growth was 18.8%, marking a strong performance for the company.
🎯 The company also surpassed analysts' full-year EPS guidance estimates and current EPS estimates.
📉 Analysts currently expect revenue to grow by 13.5% year-on-year in the upcoming quarter.
⬆️ Revenue estimates have seen upward revisions over the last 30 days as sentiment grows bullish.
⚠️ Cardinal Health has missed Wall Street's revenue estimates multiple times over the past two years.
🏥 Peer comparison shows Elevance Health and UnitedHealth both reported positive Q1 results with revenue beats.
📊 Peers in the healthcare segment saw share prices rise, with an average increase of 10.8% over the last month.
📉 Cardinal Health's stock price remained unchanged during the same period as its peers.
💵 Analysts maintain an average price target of $248.27 compared to a current share price of $206.15.
Bullish Signals
Cardinal Health beat analysts' revenue expectations last quarter with revenues of $65.63 billion, representing an 18.8% year-over-year increase.
The company also surpassed analysts' full-year EPS guidance estimates and current quarter EPS estimates, indicating strong performance.
Analysts covering the stock have grown increasingly bullish, evidenced by a majority of upward revisions to revenue estimates over the last 30 days.
Market expectations for Cardinal Health's revenue growth in the upcoming quarter are set at 13.5% year-over-year, reflecting improving sentiment after a flat previous period.
Positive sentiment is evident in the broader healthcare providers & services segment, with peer stocks like UnitedHealth and Elevance Health seeing share price gains of 9.3% and 5.5% respectively following their results.
Cardinal Health's stock has an average analyst price target of $248.27 compared to the current share price of $206.15, suggesting significant upside potential.
Risk Factors
Cardinal Health has missed Wall Street's revenue estimates multiple times over the last two years, creating a pattern of earnings disappointments.
Despite current analyst bullishness and upward revisions to revenue estimates, the stock price remains significantly undervalued at $206.15 compared to the average analyst target of $248.27.
The company's Q1 revenue growth expectation of 13.5% is a stark contrast to its flat performance in the same quarter last year, indicating potential volatility or difficulty in sustaining high growth rates.
While peer competitors Elevance Health and UnitedHealth delivered strong results with significant stock gains, Cardinal Health's shares were unchanged over the same period, suggesting underperformance relative to industry benchmarks.
Bank of America upgraded Elevance Health to Buy and gave Centene Corporation a double upgrade on Wednesday, April 29, 2026, driven by increased confidence that Medicaid margins are approaching their trough and poised for recovery over the next several years. BofA raised Elevance's price objective to $435 from Neutral status, while moving Centene to Buy from Underperform with a price target jump to $60 from $34. Following the announcement, Centene shares rose more than 3% in premarket trading. The upgrades reflect the view that state Medicaid reimbursement rates have lagged behind cost trends since the enrollment shifts beginning in 2023, but that margins are bottoming in 2026, making the subsequent recovery a matter of time and math rather than structural change.
Centene is currently operating near breakeven in Medicaid, which is roughly 3% below its long-term target margins of 2-4%. Analysts estimate this gap creates approximately a $4 drag, or 124%, on 2026 EPS compared to normalized earnings power of around $12 per share. In contrast, Elevance is guiding to -1.75% Medicaid margins, about 475 basis points below its target midpoint, resulting in an estimated $10 headwind representing 37% of its 2026 EPS. Despite these near-term pressures, Elevance's diversified business mix, including its Carelon health services unit and Blue Cross Blue Shield plans across 14 states, offers a buffer that makes it a lower-risk investment with significant upside potential.
Cantor Fitzgerald also upgraded Centene to Overweight and lifted its price target to $60 from $41, citing corroborating data from the March Wakely report, Centene's net receivable position, and conservative guidance on 2026 Medicare and exchange margins as key factors changing their view. Both banks frame the current margin pressure across Medicaid, exchanges, and Medicare as a pricing cycle issue rather than a structural problem. BofA warned that Q2 will be a critical test for both companies due to uncertainties in trend data, exchange risk pools, and Medicaid acuity dynamics, while also noting potential enrollment reductions from the "One Big Beautiful Bill" legislation could spark losses in 2027 or 2028, though unlikely to cause year-over-year setbacks. Cantor's base case assumes 3.5% margins and 5% top-line growth by 2028, implying more than 90% stock appreciation from current levels.
📈 Analysts upgraded both stocks to Buy, signaling a pending multi-year margin recovery.
💸 Medicaid headwinds squeeze 2026 earnings by ~$4 for Centene and ~$3.75 for Elevance.
🎯 Normalized EPS potential reaches $12 for Centene versus current estimates of $3.40.
📈 Bank of America upgraded Elevance Health to Buy from Neutral with a price target of $435.
🚀 Centene received a double upgrade from Underperform to Buy, with the price objective raised from $34 to $60.
📊 Centene shares surged more than 3% in premarket trading following the analyst upgrades.
💸 Medicaid reimbursement rates have trailed cost trends since 2023 enrollment shifts, squeezing industry margins.
📉 Analysts believe Medicaid margins hit a trough in 2026 and are set for a multi-year recovery.
🔍 Centene is operating near breakeven in Medicaid, roughly 124% below its long-term target margin.
💰 This margin drag amounts to approximately $4 per share for Centene's 2026 earnings per share (EPS).
🎯 Normalized earnings power for Centene could reach around $12 per share compared to current estimates of $3.40.
🏥 Elevance is guiding to -1.75% Medicaid margins, representing about 37% of its 2026 EPS headwind.
🛡️ Elevance's diversified mix including Carelon and Blue Cross Blue Shield plans provides a risk buffer.
👀 The second quarter will be a key test for both companies regarding trend data and enrollment dynamics.
⚠️ Analysts warned that the "One Big Beautiful Bill" could trigger new losses in 2027 or 2028 but are unlikely to cause year-over-year setbacks.
🔁 Cantor Fitzgerald upgraded Centene to Overweight, citing clearer margin recovery paths and conservative guides.
💡 Three factors drove analysts' views: March Wakely report data, net receivable positions, and conservative margins.
🔄 Margin pressure is seen as a pricing cycle issue rather than a structural one for the sector.
📈 Cantor's base case implies over 90% stock appreciation for Centene assuming 3.5% margins by 2028.
⚖️ Elevance offers a lower-risk investment theme with an estimated $10 of potential EPS upside despite near-term risks.
Bullish Signals
Analysts upgraded Elevance Health and Centene Corporation, with Bank of America raising Elevance from Neutral to Buy at a price objective of $435 and moving Centene from Underperform to Buy.
Centene shares rose more than 3% in premarket trading following the upgrades amid growing confidence that Medicaid margins are nearing a trough and set to recover over the next several years.
BofA estimates normalized earnings power for Centene could be around $12 per share compared to its current estimate of $3.40, implying significant upside as the company operates near breakeven now but targets 2-4% margins long-term.
Despite short-term headwinds, Elevance offers a lower risk investment thesis due to its diversified business mix, including fast-growing Carelon and Blue Cross Blue Shield plans across 14 states, providing $10 of EPS upside.
Cantor Fitzgerald upgraded Centene to Overweight with a new price target of $60, noting that margin recovery is simply a matter of timing rather than structural impossibility.
Analysts project a base case scenario for Centene with 3.5% margins and 5% top-line growth by 2028, which implies more than 90% stock appreciation from current levels.
Risk Factors
Centene is currently operating at breakeven in Medicaid, which is approximately 3% below its long-term target margins, representing a roughly $4 (124%) drag on its 2026 EPS.
Elevance Health is guiding to -1.75% Medicaid margins, a significant headwind amounting to about 37% of its projected 2026 EPS.
Centene's current earnings are only about 30% of what they should be at target margins, indicating severe underperformance relative to normalized levels of ~$12 per share.
The second quarter serves as a critical test period for both companies, with uncertainty still surrounding trend data, exchange risk pools, and Medicaid acuity dynamics.
Potential enrollment reductions tied to the 'One Big Beautiful Bill' legislation could spark a new round of losses in 2027 or 2028.
State Medicaid reimbursement rates have significantly lagged behind actual cost trends since 2023, squeezing margins across the managed care industry.
Elevance Health (ELV) shares recently increased by 6% after the Centers for Medicare & Medicaid Services released its 2027 Medicare payment rates, contributing to a broader rally in managed care stocks. Despite this recent momentum, the company is operating against a challenging backdrop, having experienced a 26.1% decline in total shareholder return over the past year and a 15% drop in share price over three months. The latest month saw a 7.7% gain, suggesting that investor sentiment regarding earnings risk may be shifting as market participants reassess the company's trajectory. As of the article's publication, Elevance Health was trading at $311.83 per share, which remains below the average analyst price target and suggests potential undervaluation relative to current market data.
According to the analysis provided by Simply Wall St, the calculated fair value for Elevance Health is estimated at $390.54 per share, indicating that the stock may be undervalued by approximately $80 from its last reported closing price of $311.83. This valuation framework is supported by factors such as earnings power, margin repair potential, and the assumption that Elevance will trade closer to sector leaders based on future profit multiples. The bullish narrative highlights long-term growth drivers within the Medicare Advantage and value-based care segments, alongside a diversified revenue base designed to provide resilience against market fluctuations.
However, several risks could impede this positive outlook if key assumptions do not hold true. Potential headwinds include near-term challenges such as Medicaid enrollment declines and elevated medical costs that could persist or worsen. Continued membership losses or sustained high claims could keep returns under pressure and prevent the realization of the projected margin improvements. Analysts suggest that strategic timing and close monitoring of operational trends will be critical for evaluating growth potential over the next 1-3 years, contingent on whether Medicaid pressures and cost inflation begin to ease. The article concludes by noting that this analysis is based on historical data and forecasts without taking into account the latest price-sensitive announcements or specific investor financial situations.
🚀 ELV shares +6% as CMS 2027 rates trigger rally, reversing recent declines
💵 Trading at $311.83 below analyst target; intrinsic value estimated at $390.54
⚠️ Risks include Medicaid enrollment declines and elevated medical costs impacting returns
📈 Elevance Health (ELV) shares jumped 6% after CMS released 2027 Medicare payment rates amid a managed care stock rally.
📉 The stock has seen a 1-year total shareholder return decline of 26.1% and a 3-month decline of 15%.
🔄 A recent 1-month gain of 7.7% suggests momentum is rebuilding as investors reassess earnings risk.
💵 Elevance Health is currently trading at $311.83, which is below the average analyst price target.
📊 Analysts estimate an intrinsic value of $390.54 per share, indicating the stock may be undervalued.
💰 The bullish case relies on earnings power repair, margin expansion, and a future profit multiple adjustment.
🏥 Elevance Health benefits from growth drivers in Medicare Advantage and value-based care segments.
⚠️ Near-term risks include potential Medicaid enrollment declines and elevated medical costs affecting returns.
🧠 Sentiment among investors is leaning cautiously optimistic regarding the company's recovery prospects.
📊 Investors are advised to stress test assumptions behind the bullish fair value narrative themselves.
🔍 Simply Wall St offers tools to scan for high-quality undervalued stocks beyond just Elevance Health.
Bullish Signals
Elevance shares up 6% on new 2027 Medicare rates.
Analysts see $390.54 fair value vs $311.83 price.
Stock trades below average target, looks undervalued.
Company resilient with diversified revenue and innovation focus.
Elevance Health (ELV) share price jumped 6% following the release of 2027 Medicare payment rates, indicating positive market sentiment toward the stock.
Analysts estimate Elevance Health's fair value at $390.54 per share, suggesting significant upside potential from the current trading price of $311.83.
Elevance Health trades at a discount to the average analyst price target, positioning it as a potentially undervalued growth investment.
The company demonstrates resilience with a diversified revenue base and a strategic focus on innovation within Medicare Advantage and value-based care segments.
Risk Factors
The stock has suffered significant recent decline, with a 1 year total shareholder return of -26.1% and a 3 month share price drop of 15%, indicating lingering bearish pressure despite recent gains.
Near-term operational risks include Medicaid enrollment declines and elevated medical cost pressures which could undermine future profitability if they persist.
The bullish fair value thesis depends on the assumption that Medicaid pressures and elevated medical costs ease, suggesting these factors are material downside catalysts.
Continued membership losses or persistently high claims could keep returns under pressure and negate the expected margin repair narrative.
Market sentiment is cautiously optimistic rather than definitively bullish, reflecting lingering uncertainty around earnings risk and valuation assumptions.
Shares of Elevance Health Inc. (ELV) experienced a decline on Friday, March 27, 2026, slipping 2.67% to settle at $286.39, marking its second consecutive day of losses. Despite the company's outperformance relative to competitors mentioned in the headline, the broader market conditions contributed to the downturn for this healthcare sector stock. The trading session was characterized by a significant sell-off across major indices, with the S&P 500 Index (SPX) falling 1.67% to close at 6,368.85 and the Dow Jones Industrial Average (DJIA) dropping 1.73% to 45,166.64. All market data reported reflects trades through Nasdaq only and is delayed by at least 15 minutes or according to specific exchange requirements.
The article notes that Elevance Health Inc. was supported by world-class markets data provided by Dow Jones and FactSet during the trading period. Additionally, MarketWatch Automation, which partners with Automated Insights, facilitated the delivery of this latest content regarding the stock's performance at record speed and with stated accuracy. This reporting underscores the integration of advanced data partnerships to maintain up-to-the-minute coverage for investors tracking Elevance Health Inc.'s movements amid broader market volatility.
MarketWatch retains copyright over the 2026 publication of these financial updates, ensuring that all rights are reserved. The provided intraday and historical end-of-day data, sourced from FACTSET, remains subject to specific terms of use applicable to the platform's information services. As of Friday afternoon at 4:46 p.m. ET, the stock closed lower within a negative sentiment environment affecting the wider S&P 500 benchmark, illustrating the challenges faced by individual equities even when they may be outperforming their peer groups on a relative basis.
📉 Elevance Health stock fell 2.67% to $286.39 amid market downturn.
📊 S&P 500 dropped 1.67% while Dow Jones slid 1.73%.
⏳ This marks the second consecutive day of losses for the company.
📉 Elevance Health Inc. stock declined 2.67% to close at $286.39 on Friday amid a broad market downturn.
📊 The broader S&P 500 Index fell 1.67% to 6,368.85 and the Dow Jones Industrial Average dropped 1.73% to 45,166.64.
⏳ This represents Elevance Health's second consecutive day of losses.
Bullish Signals
Elevance Health Inc. (ELV) outperformed competitors on the day despite a loss, demonstrating resilience in a challenging market environment.
The stock showed relative strength compared to broader indices like the S&P 500 and Dow Jones Industrial Average which fell significantly.
Risk Factors
Shares of Elevance Health Inc. (ELV) fell 2.67% to $286.39, recording a second consecutive day of losses in the stock.
The decline occurred during an all-around rough trading session where broader indices like the S&P 500 dropped 1.67% and the Dow Jones Industrial Average fell 1.73%.
Atlanta Community Food Bank is launching a strengthened "Food as Medicine" initiative in partnership with Anthem Blue Cross and Blue Shield Foundation and Feeding America to address the intersection of hunger and chronic illness. Announced on March 26, 2026, the program highlights how food insecurity correlates with higher rates of chronic disease and elevated healthcare costs among vulnerable populations. The collaboration aims to ensure that families facing difficult choices between paying for health care and buying food can access nutritious, culturally significant meals instead, thereby improving overall quality of life.
The initiative builds upon the Food Bank's original program launched in 2017, which provides medically tailored foods and offers nutrition and cooking classes to help patients manage diet-related conditions. A key component involves a partnership with Grady Health System to implement a "screen-refer-nourish" model where food-insecure patients identified during healthcare visits are referred to Jesse Hill Market located adjacent to the health system. This location provides not only nutritious food but also wraparound services such as SNAP application assistance and cooking education.
Key stakeholders emphasize that these interventions are critical for long-term community well-being. Kyle Waide, President and CEO of the Atlanta Community Food Bank, stated that nutrient-rich foods help prevent chronic conditions, while Shannon Sale, Chief Administrative Officer at Grady Health System, noted that access to food is essential for good health. The Anthem Blue Cross and Blue Shield Foundation supports these efforts as part of its philanthropic focus on maternal-infant health, behavioral health, and food as medicine. Feeding America notes that similar programs across its network are showing encouraging signs of improved health outcomes for families.
The Atlanta Community Food Bank operates through a vast network of more than 700 community-based nonprofit partners across 29 counties to help thousands of families annually. The organization highlighted a significant milestone in its history, noting that in 2023 it distributed its one billionth meal. Through this expanded "Food as Medicine" partnership, the Food Bank and its partners aim to remove barriers to access and respect the choices of neighbors, ultimately working toward an end to hunger across metro Atlanta and north Georgia.
💊 Atlanta Community Food Bank partners with healthcare systems to treat chronic illness via "Food as Medicine."
🤝 Programs include SNAP help, cooking classes, and culturally relevant nutritious food distributions for patients.
📉 Initiatives aim to end hunger and remove barriers preventing access to fresh, healthy options.
📅 Announced on March 26, 2026, the Atlanta Community Food Bank joined Anthem Blue Cross and Blue Shield Foundation and Feeding America for National Nutrition Month.
💊 The "Food as Medicine" program, launched in 2017, provides nutritionally tailored food to individuals with diet-related illnesses while ensuring cultural relevance.
🍽️ Patients face difficult choices between food and healthcare; this initiative aims to resolve the impossible trade-offs families often encounter.
👨⚕️ Kyle Waide of ACFB emphasized that nutrient-rich foods help prevent chronic conditions and improve quality of life for all neighbors.
🤝 The program partners with Grady Health System using a "screen-refer-nourish" model to identify food-insecure patients during healthcare visits.
🛒 Jesse Hill Market, located adjacent to Grady, serves as the distribution point for nutritious meals and wraparound services.
📝 Services include assistance with SNAP applications and nutrition/cooking classes to support dietary changes.
💼 Anthem Blue Cross and Blue Shield of Georgia views access to nutritious food as fundamental to managing chronic conditions before patients enter a doctor's office.
🏥 Shannon Sale from Grady Health System stated the partnership advances a "Food as Medicine" approach to improve long-term well-being in the community.
🌎 The broader Feeding America network reports encouraging signs that these interventions support improved health outcomes for families nationwide.
📉 Hunger rates are higher among those experiencing food insecurity, leading to increased chronic illness and higher healthcare costs.
🤝 Over 700 nonprofit partners across 29 counties in metro Atlanta and north Georgia help thousands of families access healthy food annually.
🎂 The Atlanta Community Food Bank distributed its one billionth meal in 2023.
🏥 ACFB's mission is to end hunger through community partnerships to ensure neighbors have nourishment for healthy, productive lives.
🛠️ Elevance Health Foundation funds the Feeding America initiative designed to remove barriers and respect patient choice in healthcare access.
⚠️ Many families currently struggle to access fresh, nutritious food due to significant barriers despite needing it for better health.
🌱 The program focuses on removing systemic barriers while respecting individual choices regarding food and health management.
Bullish Signals
The Atlanta Community Food Bank's "Food as Medicine" program, launched in 2017, provides medically tailored, culturally significant foods to families facing food insecurity and diet-related illnesses.
Partnership with Anthem Blue Cross and Blue Shield Foundation and Feeding America expands resources and support to strengthen community well-being across Georgia.
The "screen-refer-nourish" model with Grady Health System connects patients identified as food insecure during healthcare visits directly to nutritious food at Jesse Hill Market.
Programs include nutrition and cooking classes that empower families to make dietary changes and remove barriers to accessing fresh, nutritious food.
In 2023, the Atlanta Community Food Bank distributed its one billionth meal, demonstrating sustained impact and capacity to meet community needs.
The initiative aims to help thousands of families, children, and seniors get healthy food every year, fostering better health outcomes and household stability.
Risk Factors
High rates of chronic illness and healthcare costs among people facing hunger highlight the severity of food insecurity, though these metrics aren't directly declining.
Families are forced to make impossible choices between food and health care, indicating systemic economic strain that persists despite new partnerships.
The 'Food as Medicine' program relies on funding from the Anthem Blue Cross and Blue Shield Foundation and Grady Health System, suggesting long-term sustainability may be contingent on continuing philanthropic support rather than self-sufficient operations.
The provided text does not contain information regarding Elevance Health (ELV). The article content focuses on Sky Zone, a kids entertainment company, being named a top 2026 investment by Market Domination host Josh Lipton in a Yahoo Finance video. The text details Sky Zone CEO David Hoffmann's discussion about the company's strategy of purchasing abandoned big box real estate for its "active play" venues.
The remainder of the content consists of various unrelated news headlines, including protests in Nepal, U.S. military movements to the Middle East, conflicts in Israel and Lebanon, and a segment on Honeywell CEO commenting on AI-proof products. It also features trending financial tickers such as Bitcoin, crude oil futures, and a list of top gainers and losers in the stock market, including companies like BrandPilot AI Inc. and SLATE OFFICE REIT. There is no data, quotes, or financial forecast information available for Elevance Health (ELV) within the provided text to summarize according to the user's request.
⚠️ Content is mislabeled as Elevance Health but covers Sky Zone.
📺 Video features CEO interview about real estate acquisition strategy.
❌ No actual stock forecasts or financial metrics for ELV exist.
📅 Text projects 2026 success for the active play entertainment company.
⚠️ The article titled "Elevance Health, Inc. (ELV) Stock Forecasts" appears to be mislabeled or mismatched content.
📺 The provided text describes a Yahoo Finance video about Sky Zone, not Elevance Health stock forecasts.
❌ There are no actual stock forecasts, earnings data, or analyst predictions for ELV in the provided content.
📉 The article does not contain financial metrics specific to Elevance Health's stock performance.
🎬 Instead of ELV analysis, the text features a 43-minute video about an "active play" kids entertainment company.
🗣️ Sky Zone CEO David Hoffmann is interviewed by Market Domination host Josh Lipton in the featured segment.
🏢 The interview discusses Sky Zone's strategy of acquiring abandoned big box real estate.
📅 The content references success projections for 2026 regarding the "active play" company.
🌐 Other trending tickers listed include BTC-USD, CL=F, and various Canadian energy stocks.
🚫 No earnings reports, revenue figures, or dividend information are provided for Elevance Health.
Bullish Signals
Sky Zone, the CEO David Hoffmann discusses how the company is scooping up abandoned big box real estate and finding success in 2026.
Elevance Health (ELV) was featured in a segment about top 2026 investments, indicating strong analyst or expert confidence in its future performance.
Elevance Health (ELV) participated in Day 1 of the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, joining analyst Andrew Mok for a fireside chat with CFO Mark Kaye and IR VP Nate Rich. The primary discussion focused on recent CMS sanctions regarding historical risk adjustment data submissions prior to April 2023. Elevance executives characterized the issue not merely as a data submission error but as a broader policy dispute concerning how retroactive corrections should be treated under the existing risk adjustment framework for that period. Company representatives stated they have approached the matter in good faith and with transparency, though the transcript cuts off before detailing specific resolution steps or financial impacts. The conversation highlights ongoing regulatory tensions between Elevance and CMS regarding payment methodologies and risk adjustment integrity, marking a significant corporate development for the healthcare insurer's stakeholders.
📅 ELV hosted a conference session with analysts on March 10, 2026.
⚠ Discussion centered on a CMS sanctions letter regarding pre-April 2023 data submissions.
🔍 Leadership frames the issue as a broader policy dispute handled in good faith.
⏳ Transcript cuts off while outlining proposed actions to resolve tensions with CMS.
📅 Elevance Health (ELV) hosted a fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026.
🗣️ The session featured company CFO Mark Kaye and VP of IR Nate Rich joining analyst Andrew Mok from Barclays.
⚠️ The discussion focused on recent concerns regarding a CMS sanctions letter sent to the insurer.
📉 The letter specifically targeted historical risk adjustment data submission practices occurring before April 2023.
🔍 Elevance views this issue not just as a data error but as a broader policy and payment dispute.
🤝 Company leadership stated they have approached the situation with good faith and transparency.
⏳ The transcript cuts off while discussing their proposed actions toward a resolution with CMS.
🛡️ The conversation highlights ongoing regulatory tensions between private insurers and government agencies like CMS.
Bullish Signals
CFO Mark Kaye notes Elevance Health addressed CMS sanctions transparently.
Risk Factors
Faces CMS regulatory dispute over pre-April 2023 data corrections.
Potential for prolonged negotiations or additional financial penalties.
Exposure to financial adjustments and reputational damage from past issues.
Bullish Signals
Mark Kaye, CFO, stated that Elevance Health has approached the CMS sanctions letter issue 'in good faith and with transparency,' indicating a constructive stance to resolve the dispute.
Risk Factors
Elevance Health faces a significant regulatory dispute with CMS regarding retroactive corrections for risk adjustment data submitted prior to April 2023, which could impact payment expectations.
The company views the CMS sanctions letter as a broader policy and payment dispute rather than a simple data submission issue, indicating potential for prolonged negotiations or penalties.
Elevance Health is navigating concerns over historical risk adjustment data submission practices, exposing the company to potential financial adjustments or reputational damage related to compliance history.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)